Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who
completed the preceding primary pulmonary hypertension, double-blinded clinical trial of terbogrel (protocol 528.19)
provide informed consent to participate in this trial
are in a stable or improving medical condition, in the opinion of the investigator
enter the study immediately upon their completion of the preceding double-blind Trial 528.19, or enter the study within one month of completing the preceding trial as long as their medical condition has remained stable or continues to improve in the interim
You may not be if
Development of an unstable medical condition during or following completion of the preceding clinical trial which, in the investigator's opinion, may be worsened by treatment with terbogrel
Premature discontinuation of the preceding terbogrel clinical trial due to an adverse event or for any other reason
Pregnant or nursing women, or women of childbearing potential (less than one year postmenopausal or not surgically sterilized) who are not using adequate methods of birth control
